A1C Almanac

Main Page

The Triglyceride-to-HDL Cholesterol Ratio as a Pragmatic Index of Atherogenic Dyslipidemia, Insulin Resistance, and Cardiometabolic Longevity Risk

Posted

by

dr Karunia Valeriani Japar

Table of Contents
Category:
Tags: , ,

Keywords: Triglyceride-to-HDL Cholesterol Ratio, Atherogenic Dyslipidemia, Insulin Resistance, Metabolic Syndrome, Longevity

Introduction

Metabolic dysfunction and atherosclerotic cardiovascular disease (ASCVD) remain leading threats to both health span and lifespan worldwide, driven by rising rates of obesity, insulin resistance, and type 2 diabetes in increasingly younger populations. Although low‑density lipoprotein cholesterol (LDL‑C) has traditionally dominated cardiovascular risk assessment and treatment targets, substantial residual risk persists even among individuals who attain guideline‑recommended LDL‑C levels. This residual risk highlights the pathogenic importance of triglyceride‑rich lipoproteins, qualitative aspects of HDL function, and the broader insulin‑resistant milieu that are not fully captured by LDL‑C alone. Within this evolving framework, the triglyceride–to–HDL‑C (TG/HDL‑C) ratio has gained prominence as a simple yet powerful index that condenses features of atherogenic dyslipidemia and metabolic health into two routinely measured lipid parameters.

From a health‑optimization and longevity perspective, there is growing interest in biomarkers that are inexpensive, widely available from standard fasting blood work, and amenable to repeated measurement and integration into digital dashboards. Such markers are particularly valuable when they can be tracked over time as behavioural, nutritional, and pharmacologic interventions are implemented, providing a dynamic readout of underlying metabolic physiology rather than static risk labelling. The TG/HDL‑C ratio is uniquely attractive in this regard because it reflects not only lipid transport, but also hepatic insulin signalling, adipose tissue function, and the burden of triglyceride‑rich remnant particles that contribute to vascular inflammation and accelerated arterial aging.

In this context, TG/HDL‑C can be conceptualized as a pragmatic bridge between traditional lipidology, cardiometabolic medicine, and emerging longevity‑focused practice. This article reviews the biological and pathophysiological rationale for TG/HDL‑C as a key health indicator, synthesizes current evidence linking the ratio to insulin resistance, metabolic syndrome, and cardiovascular risk, and discusses its potential role in assessing and modifying cardiometabolic aging. Finally, we explore how clinicians and AI‑enabled health‑technology platforms can deploy TG/HDL‑C as a practical, scalable lever in prevention‑focused, precision, and biohacking‑oriented care models.

Biological and Pathophysiological Rationale

Triglycerides and HDL‑C are tightly integrated into the regulatory network of insulin action, hepatic lipoprotein production, and peripheral lipid clearance. In physiological states, insulin suppresses hepatic very‑low‑density lipoprotein (VLDL) secretion, promotes adipose tissue lipid storage, and facilitates efficient clearance of triglyceride‑rich lipoproteins via lipoprotein lipase–mediated hydrolysis. In insulin‑resistant states, this coordination breaks down: hepatic VLDL production increases, adipose tissue becomes a net source rather than a sink for free fatty acids, and the capacity of peripheral tissues to clear circulating triglyceride‑rich particles is diminished. The net effect is an elevation in fasting triglycerides that reflects both increased production and impaired catabolism, a pattern that is further amplified in the presence of visceral adiposity and non-alcoholic fatty liver disease [1,2,3,4,5].

Beyond quantitative elevations in triglycerides, insulin resistance and chronic overnutrition qualitatively remodel the lipoprotein landscape. Enhanced activity of cholesterol ester transfer protein (CETP) under hypertriglyceridemic conditions promotes the exchange of triglycerides from VLDL and remnants into HDL and LDL particles in exchange for cholesterol esters. This CETP‑mediated remodelling generates triglyceride‑enriched HDL and LDL, which are then preferential substrates for hepatic lipase, leading to the formation of smaller, denser HDL particles that are rapidly cleared from the circulation and small, dense LDL particles that are more atherogenic. These changes impair HDL‑mediated reverse cholesterol transport and increase the arterial wall penetration and retention of LDL, thereby linking disordered triglyceride metabolism to accelerated atherosclerosis [5,6,7,8,9].

Within this mechanistic framework, the TG/HDL‑C ratio functions as a composite, clinically tractable phenotype. Elevated triglycerides in the numerator signal increased flux of triglyceride‑rich lipoproteins and remnants, while reduced HDL‑C in the denominator reflects impaired reverse cholesterol transport and qualitative HDL dysfunction. Individuals with a high TG/HDL‑C ratio consistently display an atherogenic lipoprotein profile characterized by higher concentrations of small, dense LDL, apoB‑containing remnants, and elevated non‑HDL‑C at any given LDL‑C level. Conversely, a low TG/HDL‑C ratio is typically observed in the context of preserved insulin sensitivity, lower hepatic VLDL output, and larger, cholesterol‑rich, functionally competent HDL particles. Together, these features contribute to reduced endothelial injury, lower inflammatory tone, and slower progression of vascular aging, providing a biologically coherent link between this simple ratio and long‑term cardiometabolic risk [5,6,7,9,10,11].

TG/HDL-C as a Marker of Insulin Resistance and Metabolic Syndrome

Multiple cross‑sectional and longitudinal studies have demonstrated that the TG/HDL‑C ratio is closely associated with insulin resistance as quantified by surrogate indices such as HOMA‑IR, as well as by more direct measures including euglycemic clamp–derived insulin sensitivity and oral glucose tolerance–based indices. In adults without overt diabetes, higher TG/HDL‑C is consistently linked to higher fasting insulin concentrations, impaired glucose tolerance, and higher HOMA‑IR, even when LDL‑C or total cholesterol values fall within conventionally “borderline” ranges. Across diverse cohorts, individuals in the upper tertiles or quartiles of TG/HDL‑C exhibit significantly greater odds of insulin resistance compared with those in the lowest stratum, independent of BMI and central adiposity, suggesting that the ratio captures a dimension of metabolic burden not fully reflected by anthropometric parameters alone [12,13,14,15,16].

In obese and overweight children and adolescents, the TG/HDL‑C ratio also demonstrates a robust, positive association with insulin resistance and early cardiometabolic risk markers. Studies in pediatric endocrine and population‑based cohorts show that TG/HDL‑C correlates with HOMA‑IR, fasting insulin, and waist circumference, and that children in the highest TG/HDL‑C tertile have substantially higher odds of insulin resistance and metabolic syndrome compared with those in the lowest tertile. One large study of overweight and obese children aged 9–16 years reported that TG/HDL‑C was significantly higher among those with HOMA‑IR–defined insulin resistance and that those in the top tertile of TG/HDL‑C had approximately 2.5‑fold higher odds of insulin resistance after adjustment for age, sex, pubertal stage, and adiposity indices. These findings support the use of TG/HDL‑C as a practical, low‑cost tool to identify high‑risk youth who might benefit from early, intensive lifestyle or pharmacologic intervention [15,16,17].

Sex‑specific and population‑specific TG/HDL‑C cutoffs have been proposed to optimize discrimination of metabolic syndrome and insulin resistance. Early work suggested thresholds around 2.5–3.0 in men and 1.5–2.0 in women for predicting cardiometabolic clustering, although subsequent analyses have reported somewhat lower optimal values. For example, one study identified TG/HDL‑C ratios of approximately 2.97 in men and 2.24 in women as optimal cutoffs for predicting accumulation of multiple cardio‑metabolic risk factors, values notably below the conventional ratios derived from standalone triglyceride and HDL‑C thresholds. In an elderly Chinese cohort, TG/HDL‑C values exceeding 1.437 in men and 1.196 in women predicted an increased risk of metabolic syndrome, again underscoring ethnic variation and the tendency for metabolic complications to emerge at lower BMI and lipid levels in East Asian populations [13,15,18,19,20].

Despite heterogeneity in optimal cut points, a consistent pattern emerges: as TG/HDL‑C rises, insulin sensitivity declines and the burden of metabolic syndrome components, including central obesity, hypertension, hyperglycemia, and atherogenic dyslipidemia, expands across age groups and ethnicities. Conversely, lower TG/HDL‑C values are associated with a more favourable metabolic profile, including lower fasting insulin, higher insulin sensitivity indices, and reduced prevalence of metabolic syndrome. Taken together, these data support the positioning of TG/HDL‑C as a clinically useful, easily obtainable marker of insulin resistance and metabolic syndrome risk that can complement traditional lipids and anthropometrics in both adult and pediatric practice [13,14,15,17,19].

Cardiovascular risk and Atherogenic Dyslipidemia

Beyond its close relationship with insulin resistance, the triglyceride–to–HDL‑C ratio has been validated as a cardiovascular risk marker in both general and high‑risk populations. In a middle‑class urban Mexican cohort, higher TG/HDL‑C values were strongly correlated with an adverse composite lifestyle and risk‑factor score and showed stronger associations with abdominal obesity and diabetes than traditional total cholesterol/HDL‑C or LDL‑C/HDL‑C ratios. In other clinical settings, elevated TG/HDL‑C has been linked with the presence, number, and complexity of coronary plaques, with higher ratios associated with greater overall plaque burden and more extensive multivessel disease. Studies from European and Asian populations similarly report that individuals with higher TG/HDL‑C experience more incident cardiovascular events, including myocardial infarction and acute coronary syndrome, and that the ratio retains prognostic significance after adjustment for LDL‑C and established risk scores [16,21,22].

Mechanistically, TG/HDL‑C serves as a surrogate for atherogenic dyslipidemia, a lipid phenotype characterized by elevated triglycerides, low HDL‑C, an increased proportion of small dense LDL particles, and accumulation of triglyceride‑rich remnant lipoproteins. This pattern is particularly prevalent in insulin‑resistant and diabetic individuals and is strongly associated with endothelial dysfunction, pro‑inflammatory signalling, and accelerated atherogenesis. Classic cohort data, such as analyses from the Münster population, underscore the disproportionate event burden carried by individuals with this phenotype: although only a minority exhibited marked hypertriglyceridemia, low HDL‑C, and small dense LDL, they accounted for a substantial fraction of coronary events over follow‑up. More recent imaging‑based studies using coronary CT angiography have shown that higher TG/HDL‑C is independently associated with high‑risk plaque features such as positive remodelling, low attenuation plaque, and spotty calcification, even at similar levels of LDL‑C, reinforcing the concept that the ratio captures qualitative plaque vulnerability as well as quantitative plaque burden [5,7,21,23,24].

Emerging analyses indicate that TG/HDL‑C provides additive prognostic information when combined with other apoB‑related measures and composite lipid indices. Observational work suggests that TG/HDL‑C and non‑HDL‑C together may better reflect the total pool of atherogenic particles and remnant lipoproteins than either metric in isolation, improving discrimination for the presence and extent of coronary atherosclerosis. In surgical and oncology cohorts, elevated TG/HDL‑C and related ratios (e.g., non‑HDL‑C/HDL‑C) have also been associated with adverse outcomes, supporting their use as systemic risk markers beyond classical cardiovascular populations. Integrating TG/HDL‑C with non‑HDL‑C, apoB, and imaging data into multivariable risk models therefore offers a more nuanced characterization of atherogenic dyslipidemia and cardiovascular risk, positioning the ratio as a useful, low‑cost component of comprehensive risk stratification in both conventional and precision‑medicine frameworks [16,18,25,26].

Longevity, Health Span, and TG/HDL-C

While most TG/HDL‑C research has emphasized near‑term cardiometabolic endpoints, the underlying biology strongly suggests relevance for long‑term health span and longevity. Chronic exposure to insulin resistance, visceral adiposity, and triglyceride‑rich remnant lipoproteins accelerates vascular aging by promoting endothelial dysfunction, arterial stiffness, vascular calcification, and increased intima–media thickness. These disturbances are accompanied by low‑grade, systemic inflammation driven in part by small dense LDL and remnant particles, which activate innate and adaptive immune responses within the arterial wall. Over time, this combination of vascular injury and inflammatory tone contributes to the accumulation of multiple cardiometabolic conditions such as hypertension, type 2 diabetes, fatty liver disease, and ASCVD that cluster as cardiometabolic multimorbidity in later life. Within this framework, a persistently low TG/HDL‑C ratio can be viewed as a proxy for sustained insulin sensitivity, efficient handling of dietary fat, and a favourable lipoprotein milieu across decades, all of which are consistent with slower cardiometabolic aging [18,27,28].

Recent preventive cardiology and longevity‑focused practices have therefore begun to incorporate TG/HDL‑C alongside markers such as apolipoprotein B, lipoprotein(a), and high‑sensitivity C‑reactive protein to define a “metabolically youthful” cardiovascular phenotype. In this conceptual model, maintaining a low TG/HDL‑C ratio from early adulthood is hypothesized to help compress morbidity by delaying the onset of type 2 diabetes, metabolic dysfunction–associated steatotic liver disease, and clinical ASCVD events that otherwise accumulate in midlife. Supporting this notion, cohort data in women have shown that higher TG/HDL‑C predicts not only cardiovascular events but also all‑cause mortality, independent of traditional lipids and angiographic coronary disease severity, suggesting that the ratio captures a broader dimension of biological risk. At the same time, emerging geriatric data indicate that the strength of association between elevated TG/HDL‑C and incident ASCVD may attenuate in adults over 65 years, possibly reflecting survival bias or age‑related shifts in competing risks, underscoring the need for age‑specific interpretation in longevity‑oriented care [29,30,31,32].

Although long‑term longitudinal studies explicitly linking TG/HDL‑C trajectories across the life course to survival and disability‑free years remain limited, the convergence of mechanistic, metabolic, and cardiovascular evidence supports its integration into health span‑ and longevity‑focused risk assessment. In practice, tracking TG/HDL‑C over time together with other insulin‑resistance and inflammation indices may help identify individuals on a trajectory toward cardiometabolic multimorbidity and enable earlier, more aggressive intervention. Conversely, persistently low TG/HDL‑C values, in the context of favourable apoB‑related markers and inflammatory profiles, may serve as an accessible clinical signature of a more “youthful” cardiometabolic state, offering a pragmatic bridge between conventional risk factor management and modern longevity medicine [18,27,28,33,34,35,36].

Practical Measurement, Interpretation, and “Optimal” Range

TG/HDL‑C is calculated by dividing the fasting triglyceride concentration by HDL‑C, using consistent units (both in mg/dL or both in mmol/L). This simple computation can be performed from any routine fasting lipid panel, which makes the ratio readily available in primary care, community screening, and remote monitoring settings, including digital health programs. In contrast to more specialized lipid markers, no additional assays are required, lowering barriers to incorporation into everyday practice. Interpretation, however, must be contextualized by sex, ethnicity, age, comorbidities, and concomitant medications, because a single universal cut‑off has not been validated across all populations and clinical scenarios [18,37,38,39,40].

In the absence of globally accepted thresholds, many investigators and expert reviews recommend treating TG/HDL‑C as a continuous marker while using pragmatic ranges informed by epidemiologic data. Several studies and clinical commentaries note that values clearly below about 2.0 (mg/dL‑based ratio) are generally associated with more favourable cardiometabolic profiles, whereas ratios above 3–4 frequently cluster with metabolic syndrome, insulin resistance, and higher cardiometabolic risk. Pediatric and adult cohorts have proposed data‑driven cut‑offs in similar ranges, for example, TG/HDL‑C ≥2.0 in children identifying those with markedly higher cardiometabolic risk and subclinical organ changes, and values around 3–4 in adults predicting metabolic syndrome and future MetS incidence in Korean and elderly Chinese populations. Within prevention and longevity‑focused practices, some clinicians and educational sources advocate even more ambitious “optimal” targets, such as a TG/HDL‑C ratio <1.0 in mg/dL units (approximately <0.87 when expressed using mmol/L‑based ratios), as a surrogate for high‑level insulin sensitivity and a favourable lipoprotein profile [19,37,38,42].

These suggested ranges should not be interpreted in isolation; rather, TG/HDL‑C is best integrated into a multidimensional risk profile that includes anthropometrics (waist circumference, BMI), blood pressure, fasting and post‑prandial glucose parameters, ApoB or non‑HDL‑C, markers of inflammation, and, when appropriate, imaging modalities such as coronary artery calcium scoring or CT angiography. In this integrated framework, the ratio functions less as a stand‑alone diagnostic threshold and more as a high‑yield, low‑cost signal that refines global cardiometabolic and longevity risk estimation across diverse care settings [18,37,38].

Interventions to Improve TG/HDL-C

Because TG/HDL‑C reflects insulin sensitivity and triglyceride‑rich lipoprotein metabolism, it improves with lifestyle measures that target energy balance, diet quality, and physical activity. Dietary patterns lower in refined carbohydrate and added sugar, with higher intake of unsaturated fats and whole‑food fiber and moderated alcohol consumption, reduce triglycerides and can modestly raise HDL‑C, thereby lowering the ratio. Regular aerobic and resistance exercise enhances skeletal muscle insulin sensitivity and triglyceride clearance, and when combined with weight loss, particularly reduction of visceral adiposity, produces further favourable shifts in TG/HDL‑C even with modest reductions in BMI [43,44,45,46].

Pharmacologic therapy can be used when lifestyle measures are insufficient or baseline risk is high. Statins primarily reduce LDL‑C but also lower triglycerides modestly, while fibrates and high‑dose omega‑3 fatty acids more directly target hypertriglyceridemia and low HDL‑C, with outcome benefits in selected high‑risk groups. In severe or genetically driven hypertriglyceridemia, newer ApoC3‑ and ANGPTL3‑targeted agents produce large reductions in triglyceride‑rich lipoproteins and may substantially improve TG/HDL‑C, though long‑term outcome and cost‑effectiveness data are still emerging. For digital health and biohacking applications, serial TG/HDL‑C measurement offers a medium‑term feedback signal linking individualized nutrition programs, time‑restricted feeding, pharmacologic regimens, and exercise patterns to deeper improvements in metabolic resilience [18,33,38,45,47,48,49].

TG/HDL‑C is calculated by dividing fasting triglycerides by HDL‑C using consistent units (both mg/dL or both mmol/L) and can be derived from any standard fasting lipid panel, making it readily usable in primary care, community screening, and telemedicine programs. Unlike specialized lipoprotein tests, it requires no additional assays, but interpretation must consider sex, age, ethnicity, comorbidities, and medications because no single universal cut‑off applies across populations [18,19,37,38,49].

Epidemiologic and clinical studies suggest that lower TG/HDL‑C values are consistently associated with more favourable cardiometabolic profiles, with ratios clearly below about 2.0 (mg/dL‑based) generally indicating lower risk, and values above 3–4 often clustering with metabolic syndrome, insulin resistance, and higher event rates. Data‑driven cut‑offs in children and adults typically fall in this range, while some prevention and longevity‑focused clinicians advocate a more ambitious target of <1.0 as a practical surrogate for high insulin sensitivity and a favourable lipoprotein milieu. In practice, TG/HDL‑C should be interpreted within a multidimensional risk profile that includes anthropometrics, blood pressure, glucose metrics, ApoB or non‑HDL‑C, inflammation markers, and, when indicated, imaging; in this role, it serves as a high‑yield, low‑cost marker that refines global cardiometabolic and longevity risk estimation [18,19,37,38,41,42].

Integration into AI-driven and Biohacking-Oriented Care

From an AI health‑tech perspective, the TG/HDL‑C ratio is an attractive feature for risk modelling because it is inexpensive, widely available from routine lipid panels, and biologically rich as a surrogate of insulin resistance and atherogenic dyslipidemia. When combined with age, sex, BMI, blood pressure, fasting glucose, and other lipid indices, TG/HDL‑C improves discrimination for metabolic syndrome and incident cardiometabolic disease compared with models relying on single lipid parameters alone. Recent machine‑learning frameworks that predict insulin resistance or metabolic syndrome often include triglycerides, HDL‑C, or composite indices such as TG/HDL‑C and TyG, and report that these markers provide competitive or complementary predictive performance relative to traditional risk scores and anthropometric measures. Within such models, TG/HDL‑C can be used not only as a baseline predictor but also as a dynamic outcome variable, allowing algorithms to learn which sequences of lifestyle or pharmacologic interventions most effectively shift individuals toward lower‑risk phenotypes over time [18,50,51,52,53,54].

For biohackers and longevity‑focused patients who already track continuous glucose monitoring data, wearable‑derived signals, and nutrition metrics, TG/HDL‑C offers a medium‑term integrative signal linking short‑term behaviour to deeper metabolic remodelling at the lipoprotein level. Integrating TG/HDL‑C into personalized dashboards, alongside metrics such as time‑in‑range glucose, resting heart rate, heart‑rate variability, and VO₂‑linked fitness proxies can help shift user goals from transient “hacks” to sustained improvements in insulin sensitivity, remnant lipoprotein burden, and vascular health. As multi‑vital and multi‑omic digital platforms evolve, combining CGM streams with lipid‑derived risk markers in AI models enables more granular phenotyping and just‑in‑time coaching, and may reveal population‑specific thresholds and trajectories that refine the operational definition of “optimal” TG/HDL‑C across different ages, ethnicities, and baseline risk states [39,55,56].

Conclusion

The triglyceride–to–HDL‑C ratio has emerged as a simple, accessible biomarker that nonetheless encapsulates complex information about insulin resistance, atherogenic dyslipidemia, and cardiometabolic risk expression across the lifespan. In contrast to single‑analyte lipid markers, the ratio integrates hepatic triglyceride‑rich lipoprotein output, HDL metabolism, and downstream lipoprotein remodelling into a single composite index that can be derived from any standard fasting lipid panel. As such, it offers an attractive, low‑barrier entry point for both population‑level screening and individualized metabolic risk profiling in diverse clinical settings.

Across epidemiological and clinical cohorts, elevated TG/HDL‑C consistently tracks with the presence and progression of metabolic syndrome, type 2 diabetes, and a broad spectrum of cardiovascular events in both pediatric and adult populations. Higher ratios correlate with insulin resistance, visceral adiposity, small dense LDL, and triglyceride‑rich remnant lipoproteins, all of which are mechanistically linked to accelerated atherogenesis and vascular aging. Conversely, lower TG/HDL‑C ratios appear to mark a more insulin‑sensitive, cardioprotective phenotype characterized by favourable lipoprotein profiles, more efficient handling of dietary fat, and a reduced burden of cardiometabolic comorbidities, aligning this metric closely with contemporary concepts of health span and longevity.

Despite the growing body of evidence, universal TG/HDL‑C cutoffs have not yet been firmly established and clearly must be adapted to sex, ethnicity, and clinical context. Rather than a rigid threshold, the ratio is best interpreted as a continuous risk marker whose meaning is refined by accompanying anthropometric, glycemic, and lipoprotein data. Nonetheless, the available data support the integration of TG/HDL‑C into both routine clinical assessment and more sophisticated, data‑driven risk models as a low‑cost, high‑yield metric that can enhance early identification of high‑risk individuals beyond traditional lipid targets.

For clinicians and individuals focused on prevention, biohacking, and preservation of health span, actively targeting a low TG/HDL‑C ratio represents a practical and biologically coherent therapeutic lever. Lifestyle interventions, including dietary optimization, structured physical activity, and reduction of visceral adiposity alongside, when appropriate, pharmacologic strategies aimed at triglyceride‑rich lipoproteins and global risk reduction, can meaningfully improve the ratio and its underlying pathophysiology. Embedding TG/HDL‑C into longitudinal care pathways and AI‑driven monitoring systems may therefore contribute to sustained reductions in cardiometabolic burden and a deceleration of vascular aging, helping to bridge the gap between traditional risk factor management and modern longevity‑oriented medicine.

Reference

  1. Sparks JD, Sparks CE, Adeli K. Selective Hepatic Insulin Resistance, VLDL Overproduction, and Hypertriglyceridemia. Arteriosclerosis, Thrombosis, and Vascular Biology. 2012 Sep;32(9):2104–12.
  2. SADOVSKY R. Treating Dyslipidemia in Insulin Resistance. American Family Physician [Internet]. 2000 Jan 15 [cited 2026 Feb 28];61(2):496–6. Available from: https://www.aafp.org/pubs/afp/issues/2000/0115/p496.html
  3. Hirano T. Pathophysiology of Diabetic Dyslipidemia. Journal of Atherosclerosis and Thrombosis. 2018 Sep 1;25(9):771–82.
  4. Howard BV. Insulin resistance and lipid metabolism. The American Journal of Cardiology [Internet]. 1999 Jul 8;84(1A):28J32J. Available from: https://pubmed.ncbi.nlm.nih.gov/10418856/
  5. Mohanad Gabani, Shapiro MD, Toth PP. The Role of Triglyceride-rich Lipoproteins and Their Remnants in Atherosclerotic Cardiovascular Disease [Internet]. Radcliffe Cardiology. European Cardiology Review; 2023 [cited 2026 Feb 28]. Available from: https://www.ecrjournal.com/articles/role-triglyceride-rich-lipoproteins-and-their-remnants-atherosclerotic-cardiovascular
  6. Bitzur R, Cohen H, Kamari Y, Shaish A, Harats D. Triglycerides and HDL Cholesterol: Stars or second leads in diabetes? Diabetes Care. 2009 Oct 29;32(suppl_2):S373–7.
  7. Madhu K, Manjunath C, Rawal J, Irani P. Atherogenic dyslipidemia. Indian Journal of Endocrinology and Metabolism [Internet]. 2013;17(6):969. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3872713/
  8. SADOVSKY R. Treating Dyslipidemia in Insulin Resistance. American Family Physician [Internet]. 2000 Jan 15;61(2):496–6. Available from: https://www.aafp.org/pubs/afp/issues/2000/0115/p496.html
  9. Howard BV. Insulin resistance and lipid metabolism. The American Journal of Cardiology [Internet]. 1999 Jul 8;84(1A):28J32J. Available from: https://pubmed.ncbi.nlm.nih.gov/10418856/
  10. Li P, Cai J, Yuan S, Li Y, Shi H, Liang C, et al. The relationship between triglyceride to high-density lipoprotein cholesterol ratio and cardiovascular high risk: a cross-sectional investigation. Frontiers in Endocrinology [Internet]. 2025 Nov 27 [cited 2026 Feb 28];16. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC12695605/
  11. Quispe R, Manalac RJ, Faridi KF, Blaha MJ, Toth PP, Kulkarni KR, et al. Relationship of the triglyceride to high-density lipoprotein cholesterol (TG/HDL-C) ratio to the remainder of the lipid profile: The Very Large Database of Lipids-4 (VLDL-4) study. Atherosclerosis. 2015 Sep;242(1):243–50.
  12. Uruska A, Zozulinska-Ziolkiewicz D, Niedzwiecki P, Pietrzak M, Wierusz-Wysocka B. TG/HDL-C ratio and visceral adiposity index may be useful in assessment of insulin resistance in adults with type 1 diabetes in clinical practice. Journal of Clinical Lipidology. 2018 May;12(3):734–40.
  13. Zahraa Abdul Ghani, Hussein Qaddori, Qasim Al-Mayah. Triglyceride/high-density lipoprotein ratio as a predictor for insulin resistance in a sample of healthy Iraqi adults. Journal of medicine and life. 2023 May 1;16(5):668–74.
  14. Ren X, Chen Z, Zheng S, Han T, Li Y, Liu W, et al. Association between Triglyceride to HDL-C Ratio (TG/HDL-C) and Insulin Resistance in Chinese Patients with Newly Diagnosed Type 2 Diabetes Mellitus. PLOS ONE. 2016 Apr 26;11(4):e0154345–5.
  15. Iwani NAKZ, Jalaludin MY, Zin RMWM, Fuziah MZ, Hong JYH, Abqariyah Y, et al. Triglyceride to HDL-C Ratio is Associated with Insulin Resistance in Overweight and Obese Children. Scientific Reports. 2017 Jan 6;7(1).
  16. Bahar Akin S. Diagnostic Performance of Triglyceride/High-Density Lipoprotein Cholesterol (TG/HDL-C) Ratio in Detecting Insulin Resistance Among Obese Children and Adolescents. Cureus. 2026 Feb 5;
  17. DEMİRAL M. A novel diagnostic tool in determining insulin resistance in obese children: Triglyceride / HDL ratio. Journal of Surgery and Medicine. 2021 Nov 1;5(11):1144–7.
  18. Kosmas CE, Rodriguez Polanco S, Bousvarou MD, Papakonstantinou EJ, Peña Genao E, Guzman E, et al. The Triglyceride/High-Density Lipoprotein Cholesterol (TG/HDL-C) Ratio as a Risk Marker for Metabolic Syndrome and Cardiovascular Disease. Diagnostics. 2023 Mar 1;13(5):929.
  19. Nie G, Hou S, Zhang M, Peng W. High TG/HDL ratio suggests a higher risk of metabolic syndrome among an elderly Chinese population: a cross-sectional study. BMJ Open. 2021 Mar;11(3):e041519.
  20. Sarbini D, Zulaekah S, Kisnawaty SW, Isnaeni FN, Pratiwi WW, Sukmawati M, et al. TG/HDL-C ratio as a risk marker for metabolic syndrome and atherosclerosis in adolescents aged 15-18 years in Indonesia. AcTion: Aceh Nutrition Journal [Internet]. 2025 Mar 15 [cited 2026 Feb 28];10(1):124. Available from: https://ejournal.poltekkesaceh.ac.id/index.php/an/article/view/2280
  21. Koide Y, Miyoshi T, Nishihara T, Nakashima M, Ichikawa K, Miki T, et al. The Association of Triglyceride to High-Density Lipoprotein Cholesterol Ratio with High-Risk Coronary Plaque Characteristics Determined by CT Angiography and Its Risk of Coronary Heart Disease. Journal of Cardiovascular Development and Disease. 2022 Sep 28;9(10):329.
  22. Aydin F, Murat B, Murat S, Dağhan H. TG/HDL-C Ratio as a Superior Diagnostic Biomarker for Coronary Plaque Burden in First-Time Acute Coronary Syndrome. Diagnostics. 2025 Sep 2;15(17):2222.
  23. Vekic J, Zeljkovic A, Cicero AFG, Janez A, Stoian AP, Sonmez A, et al. Atherosclerosis Development and Progression: The Role of Atherogenic Small, Dense LDL. Medicina [Internet]. 2022 Feb 16;58(2):299. Available from: https://www.mdpi.com/1648-9144/58/2/299
  24. Bekbossynova M, Saliev T, Ivanova‑Razumova T, Andossova S, Kali A, Myrzakhmetova G. Small dense LDL: An underestimated driver of atherosclerosis (Review). Molecular Medicine Reports. 2025 Sep 24;32(6):1–19.
  25. Kong L, Zhao Q, Han Z, Xue W, Hu Z, Niu Z, et al. Prognostic significance of TG/HDL-C and non-HDL-C/HDL-C ratios in patients with non-small cell lung cancer: a retrospective study. Journal of International Medical Research. 2022 Aug;50(8).
  26. Discordance Among ApoB, non–HDL-C, and Triglycerides for CV Prevention – American College of Cardiology [Internet]. American College of Cardiology. 2024. Available from: https://www.acc.org/Latest-in-Cardiology/Journal-Scans/2024/05/20/03/46/discordance-among-apob
  27. Tian Z, Yang L, Li Y, Huang Y, Yang J, Xue F. Associations of different insulin resistance-related indices with the incidence and progression trajectory of cardiometabolic multimorbidity: a prospective cohort study from UK biobank. Cardiovascular Diabetology. 2025 Jun 18;24(1).
  28. Jiang WZ, Fan ZL, Xu ML, Qian EH, Lu KD. Association between insulin resistance and multiple chronic diseases: a cross-sectional study from CHARLS. Journal of Health Population and Nutrition. 2025 May 9;44(1).
  29. Adeva-Andany MM, Ameneiros-Rodríguez E, Fernández-Fernández C, Domínguez-Montero A, Funcasta-Calderón R. Insulin resistance is associated with subclinical vascular disease in humans. World Journal of Diabetes. 2019 Feb 15;10(2):63–77.
  30. Bonomini F, Rodella LF, Rezzani R. Metabolic Syndrome, Aging and Involvement of Oxidative Stress. Aging and Disease [Internet]. 2015 [cited 2019 Oct 20];6(2):109. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4365955/
  31. Gómez-Sánchez L, Gómez-Sánchez M, Lugones-Sánchez C, Tamayo-Morales O, González-Sánchez S, Rodríguez-Sánchez E, et al. Association of Insulin Resistance with Vascular Ageing in a General Caucasian Population: An EVA Study. Journal of Clinical Medicine [Internet]. 2021 Dec 8 [cited 2025 Dec 11];10(24):5748. Available from: https://www.mdpi.com/2077-0383/10/24/5748?utm_source=chatgpt.com
  32. Izumida T, Nakamura Y, Hino Y, Ishikawa S. Combined Effect of Small Dense Low-Density Lipoprotein Cholesterol (sdLDL-C) and Remnant-Like Particle Cholesterol (RLP-C) on Low-Grade Inflammation. Journal of Atherosclerosis and Thrombosis. 2020 Apr 1;27(4):319–30.
  33. Bittner V, Johnson BD, Zineh I, Rogers WJ, Vido D, Marroquin OC, et al. The triglyceride/high-density lipoprotein cholesterol ratio predicts all-cause mortality in women with suspected myocardial ischemia. American Heart Journal [Internet]. 2009 Mar [cited 2022 Aug 2];157(3):548–55. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2677623/
  34. Wang Y, Bi L, Li Q, Wang Q, Lv T, Zhang P. Remnant cholesterol inflammatory index and its association with all-cause and cause-specific mortality in middle-aged and elderly populations: evidence from US and Chinese national population surveys. Lipids in Health and Disease [Internet]. 2025 Apr 24 [cited 2026 Feb 28];24(1). Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC12020154/
  35. Zhang R, Ma J, Wang L. Cardiometabolic multimorbidity in relation to the metabolic score for insulin resistance and creatinine-to-cystatin C ratio in a middle-aged and aged population. Frontiers in Endocrinology. 2025 Dec 1;16.
  36. Discordance Among ApoB, non–HDL-C, and Triglycerides for CV Prevention – American College of Cardiology [Internet]. American College of Cardiology. 2024. Available from: https://www.acc.org/Latest-in-Cardiology/Journal-Scans/2024/05/20/03/46/discordance-among-apob
  37. Borrayo G. Tg/Hdl-C Ratio as Cardio-Metabolic Biomarker even in Normal Weight Women. Acta Endocrinologica (Bucharest). 2018;14(2):261–7.
  38. Kim JY, Lee T, Chung TH. Predictive cut-off values for the triglyceride-to-high-density lipoprotein cholesterol ratio to predict metabolic syndrome in the middle-aged Korean population. Nutrition, metabolism, and cardiovascular diseases : NMCD [Internet]. 2024 Apr;34(4):882–92. Available from: https://pubmed.ncbi.nlm.nih.gov/38413357/
  39. Ebrahimi A, Farahnaz Joukar, Kourosh Mojtahedi, Saman Maroufizadeh, Soheil Hassanipour, Naghipour MR, et al. The predictive value of the TG/HDL index for metabolic syndrome and its components: A cross-sectional study in the PERSIAN Guilan Cohort Population. Endocrine and Metabolic Science. 2025 Aug 6;19:100269–9.
  40. Nie G, Hou S, Zhang M, Peng W. High TG/HDL ratio suggests a higher risk of metabolic syndrome among an elderly Chinese population: a cross-sectional study. BMJ Open. 2021 Mar;11(3):e041519.
  41. Liao Y, Wan Q, Hu H, Song H. Association between the ratio of triglyceride to high-density lipoprotein cholesterol (TG/HDL-c) and chronic kidney disease risk: a large-scale cross-sectional study in a Chinese population. Frontiers in Medicine [Internet]. 2025 Oct 31 [cited 2026 Feb 9];12. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC12615472/
  42. Di Bonito P, Moio N, Scilla C, Cavuto L, Sibilio G, Sanguigno E, et al. Usefulness of the High Triglyceride-to-HDL Cholesterol Ratio to Identify Cardiometabolic Risk Factors and Preclinical Signs of Organ Damage in Outpatient Children. Diabetes Care. 2011 Dec 9;35(1):158–62.
  43. Kelley GA, Kelley KS, Roberts S, Haskell W. Efficacy of aerobic exercise and a prudent diet for improving selected lipids and lipoproteins in adults: a meta-analysis of randomized controlled trials. BMC Medicine. 2011 Jun 15;9(1).
  44. Zhao S, Zhong J, Sun C, Zhang J. Effects of aerobic exercise on TC, HDL-C, LDL-C and TG in patients with hyperlipidemia. Medicine. 2021 Mar 12;100(10):e25103.
  45. Kelly RB. Diet and Exercise in the Management of Hyperlipidemia. American Family Physician [Internet]. 2010 May 1;81(9):1097–102. Available from: https://www.aafp.org/pubs/afp/issues/2010/0501/p1097.html
  46. Smart NA, Downes D, Tom, Hada S, Dieberg G, Pearson MJ, et al. The Effect of Exercise Training on Blood Lipids: A Systematic Review and Meta-analysis. Sports Medicine [Internet]. 2024 Sep 27;55. Available from: https://pubmed.ncbi.nlm.nih.gov/39331324/
  47. Tomlinson B, Wu Q, Zhong Y, Li Y. Advances in Dyslipidaemia Treatments: Focusing on ApoC3 and ANGPTL3 Inhibitors. Journal of Lipid and Atherosclerosis [Internet]. 2024 Jan 1;13(1):2–2. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC10825570/
  48. Tae Ik Chang, Elani Streja, Soohoo M, Tae Yong Kim, Rhee CM, Kovesdy CP, et al. Association of Serum Triglyceride to HDL Cholesterol Ratio with All-Cause and Cardiovascular Mortality in Incident Hemodialysis Patients. 2017 Apr 3;12(4):591–602.
  49. Chan DC, Watts GF. ANGPTL3 and ApoC-III inhibitors for treating hypertriglyceridemia in context: horses for courses? Current opinion in lipidology [Internet]. 2024 Jan;35(3):101–9. Available from: https://pubmed.ncbi.nlm.nih.gov/38372218/
  50. Lee CL, Yamada T, Liu WJ, Hara K, Yamauchi T, Yanagimoto S, et al. Machine learning-predicted insulin resistance is a risk factor for 12 types of cancer. Nature Communications [Internet]. 2026 Feb 16 [cited 2026 Feb 16];17(1). Available from: https://www.nature.com/articles/s41467-026-68355-x
  51. Yang H, Yu B, OUYang P, Li X, Lai X, Zhang G, et al. Machine learning-aided risk prediction for metabolic syndrome based on 3 years study. Scientific Reports [Internet]. 2022 Feb 10;12:2248. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8831522/
  52. Choe EK, Rhee H, Lee S, Shin E, Oh SW, Lee JE, et al. Metabolic Syndrome Prediction Using Machine Learning Models with Genetic and Clinical Information from a Nonobese Healthy Population. Genomics & Informatics [Internet]. 2018 Dec 27;16(4):e31–1. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC6440667/
  53. Shin D. Prediction of metabolic syndrome using machine learning approaches based on genetic and nutritional factors: a 14-year prospective-based cohort study. BMC Medical Genomics. 2024 Sep 4;17(1).
  54. Li Z, Wu W, Kang H. Machine Learning-Driven Metabolic Syndrome Prediction: An International Cohort Validation Study. Healthcare [Internet]. 2024 Dec 13 [cited 2025 Feb 26];12(24):2527–7. Available from: https://www.mdpi.com/2227-9032/12/24/2527
  55. Zakaria H, Roman I, Almarzooqi I, Hashemi A. Integrating Wearables Into a Hybrid Care Model: Continuous Remote Monitoring of a Diabetic Patient With Frequent Premature Ventricular Contractions Using an ŌURA Ring. Cureus [Internet]. 2025 Winter;17(6):e86174. Available from: https://pubmed.ncbi.nlm.nih.gov/40677442/
  56. Forte JC, Gannamani R, Folkertsma P, Kumaraswamy S, Mount S, Dam S van, et al. Changes in Blood Lipid Levels After a Digitally Enabled Cardiometabolic Preventive Health Program: Pre-Post Study in an Adult Dutch General Population Cohort. JMIR Cardio [Internet]. 2022 Mar 23;6(1):e34946. Available from: https://cardio.jmir.org/2022/1/e34946

‌

Discover more from A1C Almanac

Subscribe now to keep reading and get access to the full archive.

Continue reading